Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.64 |
| ▸ | PDE4A | P27815 | 2/20 | 0.64 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.64 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6660538 | 0.93 | PDE4B (0.74) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL6660929 | 0.86 | PDE4B (0.68) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL6656365 | 0.84 | PDE4B (0.73) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL6971627 | 0.81 | PDE4B (0.69) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL7798626 | 0.79 | PDE4B (0.55) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL6656546 | 0.79 | PDE4B (0.78) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL6656015 | 0.79 | PDE4B (0.59) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL7800497 | 0.77 | PDE4B (0.46) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL6657361 | 0.77 | PDE4B (0.50) | PDE4BPDE4DPDE4APDE4CPDE3B | |
| SCHEMBL144556 | 0.76 | PDE4B (0.62) | PDE4BPDE4DPDE4APDE4CPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6531473-B2 | Phosphodiesterase inhibitor; antiinflammatory agents | MERCK PATENT GMBH (DE) | 2003-03-11 | — | — | US | disclosed |
| US-20020111356-A1 | Arylalkylpyridazinones | MERCK KGAA (DE) | 2002-08-15 | — | — | US | disclosed |
| US-6399611-B1 | 2-(4-ETHOXYCARBONYLAMINOBENZYL)-6-(3,4 -DIMETHOXYPHENYL)-2,3,4, 5-TETRAHYDROPYRIDAZIN-3-ONE OR ALTERNATELY BENZYL SUBSTITUTED COMPOUNDS; PHOSPHODIESTERASE IV AND TUMOUR NECROSIS FACTOR INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-06-04 | — | — | US | disclosed |
| EP-0738715-A2 | Arylalkyl-pyridazinones | MERCK PATENT GmbH (DE) | 1996-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111356-A1 | Arylalkylpyridazinones | PDE4A, PDE5A, PDE2A | PDE4B 8/4885PDE4D 10/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.